QR 678 & QR678 Neo Vs PRP-A randomised, comparative, prospective study.
PRP
QR678
androgenetic alopecia
hair loss
male pattern hair loss
Journal
Journal of cosmetic dermatology
ISSN: 1473-2165
Titre abrégé: J Cosmet Dermatol
Pays: England
ID NLM: 101130964
Informations de publication
Date de publication:
Nov 2020
Nov 2020
Historique:
received:
30
11
2019
accepted:
13
03
2020
pubmed:
26
4
2020
medline:
15
5
2021
entrez:
26
4
2020
Statut:
ppublish
Résumé
Hair plays a significant role in shaping the appearance of an individual. Loss of hair can lead to serious effects on social esteem of an individual. The most common cause of hair loss is Androgenetic Alopecia (AGA).This hereditary disorder followed a specific pattern causing progressive thinning of hair in both Men and Women. The aim of the current study is to compare and evaluate the efficacy of QR678 therapy versus PRP in the treatment of Male Androgenetic Alopecia. Since QR678 and QR678 Neo have been found to be formulations equivalent in efficacy, the results would be the same with either formulation. A prospective, comparative, single-blind study was carried out with 2 groups of 25 patients each. Intradermal injections of QR678 formulations and PRP were injected in group A and B respectively. Hair pull test, Video microscopic assessment, Global Photographic assessment was done and patient's subjective assessment was done through questionnaire at the end of the study. Results were evaluated after 6 months and follow up was done till 1 year. 100% reduction in hair fall was noted at the end of 6 months in the QR678 group which was maintained for 1 year. Video microscopic evaluation showed that the hair density, terminal hair density, vellus hair density and shaft diameter were significantly better in QR678 group (P < .005) than the PRP group. Since QR678 and QR678 Neo formulatons are equivalent in efficacy, the results of tthis trial can be attributed to be the same, irrespective of the formulation used. The bioengineered formulation of QR678 proved to be more beneficial for Male Androgenetic Alopecia (Male pattern hair loss) compared to PRP. A comparative study between QR678 and PRP with long term follow-up will widen our spectra of knowledge.
Sections du résumé
BACKGROUND
BACKGROUND
Hair plays a significant role in shaping the appearance of an individual. Loss of hair can lead to serious effects on social esteem of an individual. The most common cause of hair loss is Androgenetic Alopecia (AGA).This hereditary disorder followed a specific pattern causing progressive thinning of hair in both Men and Women.
AIMS
OBJECTIVE
The aim of the current study is to compare and evaluate the efficacy of QR678 therapy versus PRP in the treatment of Male Androgenetic Alopecia. Since QR678 and QR678 Neo have been found to be formulations equivalent in efficacy, the results would be the same with either formulation.
METHODS
METHODS
A prospective, comparative, single-blind study was carried out with 2 groups of 25 patients each. Intradermal injections of QR678 formulations and PRP were injected in group A and B respectively. Hair pull test, Video microscopic assessment, Global Photographic assessment was done and patient's subjective assessment was done through questionnaire at the end of the study. Results were evaluated after 6 months and follow up was done till 1 year.
RESULTS
RESULTS
100% reduction in hair fall was noted at the end of 6 months in the QR678 group which was maintained for 1 year. Video microscopic evaluation showed that the hair density, terminal hair density, vellus hair density and shaft diameter were significantly better in QR678 group (P < .005) than the PRP group. Since QR678 and QR678 Neo formulatons are equivalent in efficacy, the results of tthis trial can be attributed to be the same, irrespective of the formulation used.
CONCLUSION
CONCLUSIONS
The bioengineered formulation of QR678 proved to be more beneficial for Male Androgenetic Alopecia (Male pattern hair loss) compared to PRP. A comparative study between QR678 and PRP with long term follow-up will widen our spectra of knowledge.
Types de publication
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
2877-2885Informations de copyright
© 2020 Wiley Periodicals, Inc.
Références
Anitua E, Pino A, Jaén P, Navarro MR. Platelet rich plasma for the management of hair loss: better alone or in combination? J Cosmet Dermatol. 2019;18(2):483-486.
Kapoor R, Shome D. Intradermal injections of a hair growth factor formulation for enhancement of human hair regrowth-safety and efficacy evaluation in a first-in-man pilot clinical study. J Cosmet Laser Ther. 2018;20(6):369-379.
Khatu SS, More YE, Gokhale NR, Chavhan DC, Bendsure N. Platelet-rich plasma in androgenic alopecia: myth or an effective tool. J Cutan Aesthet Surg. 2014;7:107-110.
Trink A, Sorbellini E, Bezzola P, et al. A randomized, double-blind, placebo and active-controlled, half-head study to evaluate the effects of platelet rich plasma on alopecia areata. Br J Dermatol. 2013;169(3):690-694.
Norwood OT. Incidence of female androgenetic alopecia (female pattern alopecia). Dermatol Surg. 2001;27(1):53-54.
Ellis JA, Sinclair R, Harrap SB. Androgenetic alopecia: pathogenesis and potential for therapy. Expert Rev Mol Med. 2002;4:1-11.
Rogers NE, Avram MR. Medical treatments for male and female pattern hair loss. J Am Acad Dermatol. 2008;59:547-566.
Orme S, Cullen DR, Messenger AG. Diffuse female hair loss: are androgens necessary? Br J Dermatol. 1999;141(3):521-523.
Yip L, Zaloumis S, Irwin D. Gene-wide association study between the aromatase gene (CYP19A1) and female pattern hair loss. Br J Dermatol. 2009;161:289-294.
Rinaldi F, Sorbellini E, Coscera T. The role of platelet rich plasma to control anagen phase: evaluation in vitro & in vivo in hair transplant and hair treatment. Int J Trichology. 2011;3:S14-S15.
Parsley WM, Perez-Meza D. Review of factors affecting the growth and survival of follicular grafts. J Cutan Aesthet Surg. 2010;3(2):69-75.
Reese RJ. Autologous platelet rich plasma: what do we know? important concepts relevant to hair restoration surgery. Hair Transplant Forum Intl. 2010;20(1):14-17.
Olsen EA, Weiner MS, Delong ER, Pinnell SR. Topical minoxidil in male pattern baldness. J Am Acad Dermatol. 1985;13:185-192.
Kaufman KD, Olsen EA, Whiting D, et al. Finasteride in the treatment of androgenic alopecia. J Am Acad Dermatol. 1998;39:578-589.
Maria-Angeliki G, Alexandros-Efstratios K, Dimitris R, Konstantinos K. Platelet-rich plasma as a potential treatment for noncicatricial alopecias. Int J Trichology. 2015;7:54-63.
Katsuoka K, Schell H, Wessel B, Hornstein OP. Effects of epidermal growth factor, fibroblast growth factor, minoxidil and hydrocortisone on growth kinetics in human hair bulb papilla cells and root sheath fibroblasts cultured in vitro. Arch Dermatol Res. 1987;279:247-250.
Pietrzak WS, Eppley BL. Platelet rich plasma: biology and new technology. J Craniofac Surg. 2005;16:1043-1054.
Uebel CO, da Silva JB, Cantarelli D, Martins P. The role of platelet plasma growth factors in male pattern baldness surgery. Plast Reconstr Surg. 2006;118:1458-1466.
Semalty M, Semalty A, Joshi GP, Rawat MS. Hair growth and rejuvenation: an overview. J Dermatolog Treat. 2011;22:123-132.
Besti EE, Germain E, Kalbermatten DF, Tremp M, Emmenegger V. Platelet-rich plasma injection is effective and safe for the treatment of alopecia. Eur J Plast Surg. 2013;36:407-412.
Gkini MA, Kouskoukis AE, Tripsianis G, Rigopoulos D, Kouskoukis K. Study of platelet-rich plasma injections in the treatment of androgenetic alopecia through an one-year period. J Cutan Aesthet Surg. 2014;7:213-219.
Dhurat R, Saraogi P. Hair evaluation methods: merits and demerits. Int J Trichology. 2009;1:108-119.
Tawfik AA, Osman MA. The effect of autologous activated platelet-rich plasma injection on female pattern hair loss: a randomized placebo-controlled study. J Cosmet Dermatol. 2018;17(1):47-53.
Lynch MD, Bashir S. Applications of platelet-rich plasma in dermatology: a critical appraisal of the literature. J Dermatol Treat. 2016;27:285-289.
Kapoor R, Shome D, Vadera S. QR 678 hair growth factors formulation - In vivo cellular toxicity & In vivo animal efficacy study. Manuscript accepted; plastic and reconstructive surgery. Global Open. 2019.